HistoriquePolitiqueMedicament

www.irdes.fr Juin 2013
La politique du médicament en France
(2012). Etude comparative du prix des médicaments entre la France et l'Allemagne : Kehl:
Centre Européen de la Consommation.
Abstract: La présente étude consiste en une comparaison transfrontalière du prix des
médicaments entre les deux rives du Rhin. Tout consommateur pourra grâce à cette étude
comparer le prix des médicaments partiellement ou non remboursés dans son pays et
constater s’il est utile de les acheter de l’autre côté de la frontière ; c’est notamment le cas
pour les pilules contraceptives et les médicaments prescrits dans le cadre d’une procréation
médicalement assistée très onéreux et non remboursés en Allemagne
Cote Irdes : En ligne
http://www.europe-consommateurs.eu/fileadmin/user_upload/eu-consommateurs/P-
DFs/publications/etudes_et_rapports/medicaments-etude_complete-FR-FINAL.pdf
Godman B., Wettermark B., Sermet, et al. (2012). European payer initiatives to reduce
prescribing costs through use of generics. Gabi Journals : Generics and Biosimilars Initiative
Journal, 1 (1) : 22-27.
Abstract: Pharmaceutical expenditure is increasingly scrutinised by payers of health care in
view of its rapid growth resulting in a variety of reforms to help moderate future growth. This
includes measures across Europe to enhance the utilisation of generics at low prices. A
narrative review of the extensive number of publications and associated references from the
co-authors was conducted, supplemented with known internal health authority or web-based
articles. Each European country has instigated different approaches to generic pricing, which
can be categorised into three groups, with market forces in Sweden and UK lowering the
prices of generics to between 3–13% of pre-patent loss originator prices. Payers have also
instigated measures to enhance the utilisation of generics versus originators and patentprotected
products in a class or related class. These can be categorised under the 4Es:
education, engineering, economics and enforcement, with the measures appearing additive.
The combination of low prices for generics coupled with measures to enhance their utilisation
has resulted in appreciable cost savings in some European countries with expenditure stable
or decreasing alongside increased utilisation of products in a class. Reforms will increase as
resource pressures continue to grow with the pace of implementation being likely to
accelerate. Care though with the introduction of prescribin- g restrictions to maximise savings
as outcomes may be different from expectations
Lee D. (2012). The Pharmaceutical Price Regulation Scheme – 11th Report to Parliament :
Londres : Department of Health.
Abstract: This is the eleventh Report to Parliament on the Pharmaceutical Price Regulation
Scheme (PPRS).The PPRS is a voluntary scheme agreed between the Department of Health
and the branded pharmaceutical industry represente- d by the Association of the British
Pharmaceutical Industry (ABPI). In summary, this report highlights the following: 167
companies are signed up to the 2009 scheme and 64 companies are subject to statutory
controls under the Health Service Branded Medicines (Control of Prices and Supply of
Information); three innovation package initiatives are still ongoing but the remaining seven
have now been completed; to date, 17 PAS (patient access schemes) have been
incorporated as part of 20 pieces of National Institute for Health and Clinical Excellence
(NICE) appraisal guidance and these schemes are operational in the NHS; there have been
no proposals for price changes submitted under the flexible pricing provisions; the number of
scheme members submitting Annual Financial Returns (AFRs) in accordance with the
agreed timetable has continued to decline. In 2009, 23% of AFRs were not received by the
Department one year after the end of the financial year; and a comparison of the prices of
branded medicines in the UK with prices in a range of European countries and the USA and
Australia for 2010 shows that the UK is among the lowest compared to other European
comparator countries. However, the picture is more mixed when a five-year average
exchange rate is used
http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documen-
ts/digitalasset/dh_132793.pdf
Pôle documentation de l’Irdes – Safon M.-O., Suhard V. avec la collaboration de Pichetti S.
http://www.irdes.fr/EspaceDoc/index.htm 119/147
http://www.irdes.fr/EspaceDoc/DossiersBiblios/HistoriquePolitiqueMedicament.pdf